EASD 2024: Survodutide shows promise in overweight, obesity and MASH
At EASD 2024, Boehringer Ingelheim's survodutide, a GCGR/GLP-1R dual agonist, showed 40% of overweight/obese patients achieved >20% weight loss after 46 weeks, with no plateau. For MASH, it reduced blood pressure significantly. Safety concerns were due to rapid dose escalation, which could be mitigated by gradual escalation. No direct correlation between amino acid levels and muscle loss was found. Key opinion leaders find a GCGR/GLP-1R dual agonist desirable for weight, glucose, and blood pressure reduction, improving lipids, and sustaining metabolic rate.
Related Clinical Trials
Highlighted Terms
Related News
At EASD 2024, Boehringer Ingelheim's survodutide, a GCGR/GLP-1R dual agonist, showed 40% of overweight/obese patients achieved >20% weight loss after 46 weeks, with no plateau. For MASH, it reduced blood pressure significantly. Safety concerns were due to rapid dose escalation, which could be mitigated by gradual escalation. No direct correlation between amino acid levels and muscle loss was found. Key opinion leaders find a GCGR/GLP-1R dual agonist desirable for weight, glucose, and blood pressure reduction, improving lipids, and sustaining metabolic rate.